Allergic rhinitis: Children ≥2 years and Adolescents: Intranasal: 1 spray in each nostril 3 to 4 times daily; maximum dose: 1 spray in each nostril 6 times/day. For prophylaxis initiate prior to exposure to allergen; symptomatic relief may require 1 to 2 weeks.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
(For additional information see "Cromolyn (sodium cromoglicate) (nasal): Drug information")
Allergic rhinitis (treatment and prophylaxis): Intranasal: Instill 1 spray (5.2 mg) in each nostril 3 to 4 times daily; may be increased up to 6 times daily. For prophylaxis initiate prior to exposure to allergen; symptomatic relief may require 1 to 2 weeks.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Aerosol Solution, Nasal, as sodium:
NasalCrom: 5.2 mg/actuation (13 mL, 26 mL [DSC]) [contains benzalkonium chloride, edetate (edta) disodium]
Generic: 5.2 mg/actuation (26 mL)
Yes
NasalCrom 13 mL bottle contains 100 actuations, and the 26 mL bottle contains 200 actuations
For intranasal use only. Clear nasal passages by blowing nose prior to use.
Clear nasal passages by blowing nose prior to use. For prophylaxis, initiate prior to exposure to allergen.
Store between 20°C to 25°C (68°F to 77°F). Protect from light.
Prevent and relieve nasal symptoms of hay fever and other nasal allergies (eg, runny/itchy nose, sneezing, allergic stuffy nose) (OTC product: FDA approved in ages ≥2 years and adults)
NasalCrom may be confused with Nasacort, Nasalide
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
>10%:
Dermatologic: Burning sensation of the nose
Respiratory: Nasal mucosa irritation, sneezing, stinging sensation of the nose
1% to 10%:
Central nervous system: Headache
Gastrointestinal: Unpleasant taste
Respiratory: Cough, hoarseness, post-nasal drip
<1%, postmarketing, and/or case reports: Epistaxis
OTC labeling: When used for self-medication, do not use if hypersensitive to cromolyn or any component of the formulation.
Other warnings/precautions:
• Local nasal effects: Brief nasal stinging and/or sneezing may occur after use.
• Self-medication (OTC use): Consult a health care provider before use if you have fever, discolored nasal discharge, sinus pain, or wheezing. Discontinue use and consult a health care provider if shortness of breath, wheezing, chest tightness, hives, or swelling of the mouth or throat occurs; if you have new symptoms, symptoms worsen, or your symptoms do not improve within 2 weeks, or need to use for >12 weeks. Do not use to treat sinus infection, asthma, or cold symptoms.
None known.
There are no known significant interactions.
Cromolyn nasal spray may be useful for the treatment of allergic rhinitis in pregnant patients with mild or sporadic symptoms who are unable to take preferred medications (BSACI [Scadding 2017]).
Acts locally to reduce calcium influx which decreases histamine degranulation from mast cells (Melvin 2011).
Onset of action: Response to treatment: May occur at 1 to 2 weeks
Aerosol solution (Cromolyn Sodium Nasal)
5.2 mg/ACT (per mL): $0.50
Aerosol solution (NasalCrom Nasal)
5.2 mg/ACT (per mL): $0.65
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.